(Reuters) – The U.S. Food and Drug Administration will send drugmaker Merck & Co’s COVID-19 antiviral drug, molnupiravir, to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.
The advisory committee will weigh in on safety concerns, which have been raised by some experts, before the FDA makes a decision on authorization of the drug, the report said.
(Reporting by Amruta Khandekar; Editing by Maju Samuel)
